Octagon Capital Advisors LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 31 US equity positions worth $587.9m in its Q4 2024 13F filing. The largest position was APLSUSD at 16.3% of the reported book, followed by AVBP and DNTH. Against the Q3 2024 filing, it opened 7 new positions, added to 11 and reduced 5 among the top 31 holdings.
What did Octagon Capital Advisors LP own in Q4 2024? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD APELLIS PHARMACEUTICALS INC | 16.3% | $96.0m | 3,006,980 | 0% | held | |
| 2 | AVBP ARRIVENT BIOPHARMA INC | 9.3% | $54.9m | 2,059,387 | 4% | added | |
| 3 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 7.8% | $46.0m | 2,110,167 | 21% | added |
| 4 | CNTA CENTESSA PHARMACEUTICALS PLC | 5.7% | $33.4m | 1,993,052 | -1% | reduced | |
| 5 | VRNA VERONA PHARMA PLC | 4.5% | $26.5m | 571,264 | -69% | reduced | |
| 6 | NUVB NUVATION BIO INC | Healthcare | 4.2% | $24.5m | 9,202,907 | -24% | reduced |
| 7 | INSM INSMED INC | Healthcare | 3.9% | $22.9m | 332,000 | -24% | reduced |
| 8 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.7% | $21.6m | 2,763,000 | 112% | added |
| 9 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 3.6% | $21.1m | 488,000 | – | new |
| 10 | BRD1EUR MIND MEDICINE MINDMED INC | 3.6% | $21.0m | 3,018,000 | 0% | held | |
| 11 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.5% | $20.7m | 2,425,000 | 0% | held |
| 12 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 3.1% | $18.1m | 10,450,000 | 129% | added |
| 13 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 2.8% | $16.7m | 870,000 | 0% | held |
| 14 | GOSS GOSSAMER BIO INC | Healthcare | 2.8% | $16.6m | 18,350,000 | 100% | added |
| 15 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.7% | $15.7m | 668,000 | 154% | added |
| 16 | PHVS PHARVARIS N V | 2.5% | $14.9m | 778,000 | 25% | added | |
| 17 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 2.2% | $13.2m | 1,115,000 | 0% | held |
| 18 | MERUS N V | 2.2% | $13.0m | 308,000 | – | new | |
| 19 | ERAS ERASCA INC | Healthcare | 2.2% | $12.9m | 5,136,795 | – | new |
| 20 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.1% | $12.1m | 441,600 | -20% | reduced |
| 21 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.0% | $12.0m | 904,000 | – | new |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 2.0% | $11.6m | 1,370,000 | – | new | |
| 23 | UNCY UNICYCIVE THERAPEUTICS INC | 1.4% | $7.9m | 10,000,000 | 17% | added | |
| 24 | RGLS REGULUS THERAPEUTICS INC | 1.3% | $7.7m | 4,848,802 | 14% | added | |
| 25 | CATX PERSPECTIVE THERAPEUTICS INC | 1.3% | $7.4m | 2,304,752 | 62% | added | |
| 26 | NGNE NEUROGENE INC | 1.2% | $6.9m | 303,000 | 1920% | added | |
| 27 | ALLOVIR INC | 0.8% | $4.7m | 11,215,000 | – | new | |
| 28 | ATYR ATYR PHARMA INC | Healthcare | 0.6% | $3.3m | 900,000 | – | new |
| 29 | HELIX ACQUISITION CORP II | 0.4% | $2.6m | 250,000 | 0% | held | |
| 30 | MERSANA THERAPEUTICS INC | 0.2% | $1.4m | 992,000 | 0% | held | |
| 31 | NUVATION BIO INC | 0.1% | $830.8k | 312,336 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.